Replies to post #6729 on Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

It is absolutely in the interest of big pharma to extend the patents for co-formulation. It’s pretty straight forward:

With no co-formulation patent extension, a biosimilar maker can introduce a biosimilar agent combined with generic Rhuph20 (generic Enhanze). This will lead to loss of competitive advantage and market share for the big pharma. One of the main reasons pharma has been interested in signing up with Halo/Enhanze is for life cycle management /patent extension purposes. It will make zero sense for them to be penny-wise (royalties to Halo) and pound-foolish (loss of market share).

[Fred Kadiddlehopper]

Maybe the next presentation will have some useful info.
Unfortunately CFO Elaine Sun is the presenter and she is not good at that.